Presentation (CTI)

OBJECTIVES: To evaluate whether TrumpRx-reported Most Favored Nation (MFN) pricing achieves the administration’s objective of aligning US drug prices with ‘the lowest prices paid by other developed nations’, using an international reference pricing perspective.
METHODS: A focused cross-country price comparison was conducted using a purposive sample of eight TrumpRx listed medicines that feature prominently in administration communications, spanning GLP 1s, cardiometabolic agents, fertility treatments and inhalers. TrumpRx prices were obtained from TrumpRx.gov and benchmarked against UK NHS BNF prices and German and French ex manufacturer prices where available. Prices were converted to EUR and entered into a comparison table. TrumpRx prices were classified as lower, similar or higher than UK, German and French benchmarks, and counts summarised descriptively to test the platform’s “world’s lowest prices” claim.
RESULTS: Empirical comparisons in an 8 drug sample show German prices lower than TrumpRx for most products, and around one third cheaper at UK NHS list prices, sometimes by 60-80%. Across GLP 1s and fertility drugs, TrumpRx offers sizeable cuts versus historic US prices but European list prices often remain lower, particularly for Ozempic and Gonal f. For cardiometabolic agents (Farxiga, Repatha) and chronic therapies (Xeljanz, Bevespi), German and UK prices consistently undercut TrumpRx, with French ex manufacturer prices (where available) generally similar to or below German levels.
CONCLUSIONS: TrumpRx is a consumer-facing implementation channel that uses MFN‑anchored prices. However, these mechanisms do not represent a coherent structural convergence to EU price levels. The claim that TrumpRx delivers prices “in line with the lowest paid by other developed nations” is not supported across available comparisons; instead, MFN operates as a tool with uncertain long term implications for international price relativities and innovation incentives.